Pharma-Bio Serv, Inc. (PBSV)
PBSV is quoted over the counter, not listed on an exchange. Pharma-Bio Serv, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | PBSV, quoted over the counter |
| SEC CIK | 0001304161 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Services-Management Consulting Services |
| Business address | Dorado, PR |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-09-14 |
| Cash and burn | $1.5M cash; operating cash flow -$104K a quarter. | Report 2026-07-31 |
| Shares outstanding | 22,901,692 (2026-09-10); 22,918,092 a year earlier; 22,963,451 three years earlier. | Cover page 2026-09-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Crowe PR PSC, Guaynabo, Puerto Rico, United States | PCAOB Form AP 2026-02-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-07-31 | $2.3M | -$14K | $61K | $1.5M | No debt tags | $9.5M | 10-Q 2026-09-14 |
| Q2 2026 2026-04-30 | $2.7M | $233K | -$365K | $1.8M | No debt tags | $9.1M | 10-Q 2026-06-15 |
| Q1 2026 2026-01-31 | $2.3M | $33K | -$390K | $5.8M | No debt tags | $8.8M | 10-Q 2026-03-17 |
| Q4 2025 2025-10-31 | $2.1M | -$102 | $280K | $3.4M | No debt tags | $9.0M | 10-K 2026-01-29 |
| Q3 2025 2025-07-31 | $2.0M | -$204K | $237K | $4.0M | No debt tags | $9.2M | 10-Q 2026-09-14 |
| Q2 2025 2025-04-30 | $2.4M | $95K | -$302K | $2.1M | No debt tags | $9.6M | 10-Q 2026-06-15 |
| Q1 2025 2025-01-31 | $2.5M | $9K | -$429K | $7.3M | No debt tags | $9.6M | 10-Q 2026-03-17 |
| Q4 2024 2024-10-31 | $2.3M | $16K | $78K | $6.8M | No debt tags | $9.5M | 10-K 2026-01-29 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2009-05-05 |
| Latest annual report | 10-K/A | 2026-02-27 |
| Latest quarterly / interim | 10-Q | 2026-09-14 |
| Latest current report | 8-K | 2026-09-14 |
| Latest proxy | DEF 14A | 2026-04-16 |
Source: SEC EDGAR submissions feed, 527 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier